Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of ONT 10 and Varlilumab in Patients With Advanced Ovarian Cancer or Breast Cancer

NCT02270372 is registered in ClinicalTrials.gov with Cascadian Therapeutics Inc. as lead sponsor.

NCT NCT02270372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02270372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of ONT 10 and Varlilumab in Patients With Advanced Ovarian Cancer or Breast Cancer
Lead sponsor
Cascadian Therapeutics Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2014
Completion date
June 30, 2016
Enrollment
22 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast carcinoma, advanced ovarian carcinoma